Sequencing Systemic Therapy After Novel Hormonal Therapy in Metastatic Castration-Resistant Prostate Cancer

Key Takeaways:

• After progression on a first novel hormonal therapy (NHT), the class-level options for metastatic castration-resistant prostate cancer (mCRPC) include taxane chemotherapy, an alternative NHT, radioligand therapy in PSMA-positive disease, and PARP inhibition in HRR-mutated disease.
• Response to a second NHT after progression on a first is generally lower than to a mechanistically distinct option. The CARD trial provides prospective comparative evidence supporting cabazitaxel over an alternative NHT in post-docetaxel mCRPC previously treated with a first NHT.
• Recognizing the moment to switch mechanisms relies on more than PSA – radiographic progression criteria, pain, performance status, and the genomic and imaging profile inform the choice.

The decision point after progression on a first novel hormonal therapy (NHT) in metastatic castration-resistant prostate cancer (mCRPC) carries several class-level options, each with distinct evidence and patient-selection considerations. National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) guidance support multiple paths forward. The clinical question is not whether options exist but which fits the patient and the moment.^1,2

Class-level options after NHT

Four class-level paths anchor the post-NHT decision in mCRPC:^1,2

Alternative NHT

Switching to the other second-generation androgen-receptor pathway inhibitor (ARPI) – abiraterone after enzalutamide or enzalutamide after abiraterone – remains an option. But cross-resistance between these agents often limits response, and the option is not preferred when the patient has already progressed on a first ARPI plus a taxane.³

Taxane chemotherapy

Cabazitaxel is approved for use in mCRPC after docetaxel-containing therapy and remains a class-level option in this setting. The TROPIC trial established overall survival benefit versus mitoxantrone in the post-docetaxel population (median 15.1 vs 12.7 months; hazard ratio 0.70; p < 0.0001).⁴

The PROSELICA trial subsequently established non-inferiority of cabazitaxel 20 mg/m² compared with the approved 25 mg/m² dose, providing an option for dose modification when supportive-care considerations call for it. Docetaxel rechallenge is also a class-level option in select patients.^1,5

Radioligand therapy (RLT)

Lutetium-177–PSMA-617 is approved for PSMA-positive mCRPC in patients previously treated with at least one ARPI and who have already received taxane chemotherapy or are determined to be appropriate to delay taxane chemotherapy. In the VISION trial, RLT plus standard care prolonged imaging-based progression-free survival (iPFS) versus standard care alone (median 8.7 vs 3.4 months; hazard ratio 0.40; p < 0.001) and overall survival (median 15.3 vs 11.3 months; hazard ratio 0.62; p < 0.001). Eligibility requires PSMA-positive 68Ga-PSMA-11 PET/CT confirmation.⁷

PARP inhibition

For patients with homologous recombination repair (HRR) gene alterations – particularly BRCA1, BRCA2, or ATM – certain poly(ADP-ribose) polymerase (PARP) inhibitors are an option. In the PROfound trial, olaparib improved iPFS versus an alternative ARPI in the BRCA1/BRCA2/ATM cohort (median 7.4 vs 3.6 months; hazard ratio 0.34). Eligibility depends on confirmed HRR mutation status.^1,8

CARD evidence in context

The CARD trial is the most directly comparative prospective evidence in the specific post-docetaxel, post-first-NHT population. CARD enrolled 255 patients with mCRPC who had received prior docetaxel and progressed within 12 months on a first ARPI. Patients were randomized 1:1 to cabazitaxel 25 mg/m² with primary granulocyte colony-stimulating factor (G-CSF) prophylaxis versus the alternative ARPI.³

Cabazitaxel improved iPFS (median 8.0 vs 3.7 months; hazard ratio 0.54; p < 0.001) and overall survival (median 13.6 vs 11.0 months; hazard ratio 0.64; p = 0.008). Prostate-specific antigen (PSA) response (35.7% vs 13.5%; p < 0.001) and tumor response (36.5% vs 11.5%; p = 0.004) also favored cabazitaxel.³

What CARD establishes: In patients who have already had a first NHT and docetaxel and who progress within 12 months on a first ARPI, a mechanism switch to cabazitaxel performs better than switching to the other ARPI on multiple endpoints.³

What CARD does not establish: Data are specific to that population – generalizing to earlier-line populations or to patients who have not had docetaxel goes beyond the trial scope. Class-level options for those populations sit elsewhere in NCCN guidance.^1,3

Patient selection and timing

Recognizing the post-NHT progression moment relies on more than PSA. The Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria frame progression assessment around radiographic change (new lesions, soft-tissue progression by RECIST 1.1, or bone-scan progression per PCWG3 conventions), symptomatic progression, and PSA trajectory together rather than PSA alone. Pain progression, performance status, and patient-reported symptom burden complete the clinical picture.⁹

Patient selection for taxane chemotherapy carries familiar considerations:^3,6

• Performance status
• Organ function (hematologic, hepatic, renal)
• Prior cumulative neurotoxicity from earlier docetaxel exposure
• Infection risk
• Dental status before initiation

Cabazitaxel carries boxed warnings for neutropenia and hypersensitivity reactions; primary G-CSF prophylaxis is required in the CARD regimen and recommended in the cabazitaxel label for the post-docetaxel population.^3,6

Across the 4 class-level options, distinct adverse-event profiles inform the choice:^3,6-8

• RLT carries radiation-specific monitoring needs
• PARP inhibitors carry anemia and gastrointestinal toxicity
• Taxane chemotherapy carries the neutropenia and neuropathy considerations described
• An alternative ARPI carries the AR-pathway profile

Genomic profile (HRR, microsatellite instability [MSI] / mismatch repair–deficient [dMMR], tumor mutational burden) and imaging profile (PSMA PET status, disease distribution, visceral involvement) inform which class-level options apply.¹

In Health Union's Prostate Cancer In America 2025 community insights, mCRPC patients articulate the "what comes next" decision moment as a frequent source of uncertainty – a reframe that supports proactive structuring of the post-NHT conversation by the oncology team.¹⁰